Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    tthx1114
Previous Study | Return to List | Next Study

A Phase 1/ Phase 2 Study of TTHX1114(NM141) (INTREPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04520321
Recruitment Status : Recruiting
First Posted : August 20, 2020
Last Update Posted : September 10, 2020
Sponsor:
Information provided by (Responsible Party):
Trefoil Therapeutics, Inc.

Brief Summary:
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study that includes a non-interventional observational sub-study in which subjects will undergo (standard) ocular assessments

Condition or disease Intervention/treatment Phase
Corneal Endothelial Dystrophy Fuchs Endothelial Corneal Dystrophy Pseudophakic Bullous Keratopathy Endothelial Dysfunction Drug: TTHX1114(NM141) Other: Vehicle (placebo) Phase 1 Phase 2

Detailed Description:
This is a prospective, multi-center, randomized, masked, vehicle-controlled, dose-escalation study that will include an observational (no intervention) sub-study. Up to 71 eligible subjects with moderate to severe corneal endothelial dystrophy (defined as Endothelial Cell Density < 2000 mm^2) in at least one eye will be enrolled and randomized in the main study. The Observational Sub-study will enroll approximately 25 to 50 subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Masked, Vehicle-controlled, Dose-escalation study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral Delivery
Actual Study Start Date : August 19, 2020
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : December 2021


Arm Intervention/treatment
Placebo Comparator: Vehicle (placebo)
Placebo weekly x 4
Other: Vehicle (placebo)
Placebo

Experimental: Low dose
TTHX1114(NM141) low-dose weekly x 4
Drug: TTHX1114(NM141)
engineered FGF-1 delivered intracamerally

Experimental: Mid-dose
TTHX1114(NM141) mid-dose weekly x 4
Drug: TTHX1114(NM141)
engineered FGF-1 delivered intracamerally

Experimental: High-dose
TTHX1114(NM141) high-dose weekly x 4
Drug: TTHX1114(NM141)
engineered FGF-1 delivered intracamerally




Primary Outcome Measures :
  1. Change in Corneal Endothelial Cell Count [ Time Frame: 56 Days ]
    Measured with Specular Microscopy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Fuchs Endothelial Corneal Dystrophy, pseudophakic bullous keratopathy, or endothelial dysfunction/ insufficiency due to surgical intervention diagnosed more than 6 months prior to Study Day 0
  • Central endothelial cell count of < 2000 mm^2 in at least one eye as determined by the central reading facility

Key Exclusion Criteria:

  • Conditions that would impair examination of the anterior chamber structure
  • Ocular surgery other than cataract lens replacement within the past 6 months
  • Active extra-ocular inflammation from any non-infectious or infectious cause within the past 6 months
  • Expected or planned ocular surgery within the next 3 months
  • Currently receiving cytotoxic chemotherapy
  • Treatment with a rho kinase inhibitor within the last 3 months
  • Use of cyclosporine ophthalmic emulsion or lifitegrast ophthalmic solution in the last 30 days
  • Systemic or ophthalmic corticosteroid use in the 30 days prior to Study Day 0 unless approved by the Medical Monitor
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
  • Unwilling to use birth control

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04520321


Contacts
Layout table for location contacts
Contact: Thomas M Tremblay, RN BSN (415) 305-3491 ttremblay@trefoiltherapeutics.com

Locations
Layout table for location information
United States, California
North Bay Eye Associates, Inc. Recruiting
Petaluma, California, United States, 94954
Contact: Eduardo Chavez    707-769-2240      
United States, Florida
Site 102 Recruiting
Jacksonville, Florida, United States, 32204
United States, Illinois
Site 104 Not yet recruiting
Hoffman Estates, Illinois, United States, 60169
United States, Indiana
Price Vision Group Recruiting
Indianapolis, Indiana, United States, 46260
Contact: Marianne Price, PhD    317-814-2990    mprice@cornea.org   
United States, Missouri
Site 106 Recruiting
Kansas City, Missouri, United States, 64111
United States, New York
Site 105 Recruiting
Poughkeepsie, New York, United States, 12603
Sponsors and Collaborators
Trefoil Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Thomas M Tremblay, RN BSN Trefoil Therapeutics
Layout table for additonal information
Responsible Party: Trefoil Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04520321    
Other Study ID Numbers: TTHX-001
First Posted: August 20, 2020    Key Record Dates
Last Update Posted: September 10, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Iridocorneal Endothelial Syndrome
Fuchs' Endothelial Dystrophy
Corneal Dystrophies, Hereditary
Corneal Diseases
Eye Diseases
Iris Diseases
Uveal Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn